Loading viewer...
investor_presentation
Format: PDF investor_presentation
BridgeBio is a biopharmaceutical company focused on developing medicines for rare diseases. The company highlights its progress with 2 FDA approvals, 6 potential approvals in its first 10 years, and 30+ clinical programs initiated. Key programs include fosdenopterin for molybdenum cofactor deficiency, acoramidis, infigratinib, and encaleret.
investor_presentation
29 Pages
Raytheon Technologies Corporation
Anglo-African Minerals Q1 2019 Investment Presentation
investor_presentationinvestor_presentation
17 Pages
Anglo-African Minerals plc
ESB Green Bond Roadshow 2022
investor_presentationinvestor_presentation
31 Pages
Electricity Supply Board (ESB)